EGFR and urothelial carcinoma: Furthermore, a novel bispecific ADC targeting both EGFR and HER3, receptors implicated in urothelial carcinoma pathogenesis, has shown promising antitumor activity in a Phase I study across several tumor types, with a good overall response rate (Ma et al., 2024).